Last Updated: November 16, 2026

Autologous cultured chondrocytes on porcine collagen membrane - Biologic Drug Details

« Back to Dashboard


Summary for autologous cultured chondrocytes on porcine collagen membrane
Tradenames:1
High Confidence Patents:5
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for autologous cultured chondrocytes on porcine collagen membrane
Established Pharmacologic ClassAutologous Cultured Cell
Chemical StructureChondrocytes
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for autologous cultured chondrocytes on porcine collagen membrane Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for autologous cultured chondrocytes on porcine collagen membrane Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 10,011,811 2033-11-25 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 6,150,163 2019-01-13 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 8,029,992 2028-04-04 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 8,216,778 2028-11-06 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 8,709,711 2032-06-08 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for autologous cultured chondrocytes on porcine collagen membrane Derived from Patent Text Search

These patents were obtained by searching patent claims

MACI Market Dynamics, Patent Protection, and Financial Trajectory

Last updated: September 4, 2026

MACI, or autologous cultured chondrocytes on a porcine type I/III collagen membrane, is Vericel Corp.'s cell-based cartilage-repair product for symptomatic full-thickness cartilage defects of the knee. The product has no conventional generic or biosimilar pathway, but its commercial growth depends on orthopedic surgeon adoption, reimbursement, manufacturing capacity, patient selection, and competition from osteochondral allografts, microfracture, autologous chondrocyte implantation procedures, and future cartilage-regeneration technologies.

Vericel's MACI revenue increased sharply after FDA approval and expanded surgeon adoption. Based on Vericel's public filings, MACI generated approximately $140 million of revenue in 2023, representing roughly 70% of the company's total revenue. The product's financial trajectory remained dependent on procedure volume rather than price increases or a conventional prescription-drug launch cycle. [1]

What is MACI and how does the autologous cartilage procedure work?

MACI is an autologous cellularized scaffold product. It uses a patient's own chondrocytes, which are harvested from healthy cartilage, expanded ex vivo, seeded onto a porcine-derived collagen membrane, and implanted into the cartilage defect.

MACI product characteristics

Attribute MACI
Active biological component Autologous cultured chondrocytes
Scaffold Porcine type I/III collagen membrane
Administration Surgical implantation into a knee cartilage defect
FDA status Biologic product approved under a biologics license application
Indication Symptomatic, full-thickness cartilage defects of the knee in adults
Manufacturer Vericel Corp.
Initial U.S. approval December 2016
Primary commercial model Hospital and ambulatory surgical center procedure
Manufacturing model Patient-specific, centralized manufacturing

The FDA approved MACI for the repair of symptomatic full-thickness cartilage defects of the knee with or without bone involvement in adults. The product is implanted using an open or arthroscopic procedure and is not a conventional injectable biologic. [2]

The manufacturing process creates a commercial barrier because each product is patient-specific. A physician must obtain a cartilage biopsy, ship the tissue to Vericel, allow time for cell expansion and membrane seeding, and then coordinate implantation. This creates logistical requirements that do not apply to small-molecule generics.

How large is the MACI market?

The addressable market is the U.S. population with focal cartilage defects who are appropriate candidates for surgical repair and can obtain reimbursement. MACI does not compete across the entire osteoarthritis market. Patients with diffuse degenerative osteoarthritis, advanced joint-space loss, or unsuitable anatomy may be directed toward other procedures, including osteotomy or knee replacement.

Main market drivers

MACI demand is influenced by:

  1. Increasing recognition of cartilage preservation in younger and middle-aged patients.
  2. Growth in sports-medicine procedures.
  3. Greater surgeon familiarity with cell-based cartilage repair.
  4. Hospital and payer acceptance of tissue-engineered products.
  5. Expansion of orthopedic ambulatory surgery infrastructure.
  6. Avoidance or delay of total knee arthroplasty in selected patients.

Vericel has reported that MACI adoption is concentrated among orthopedic surgeons who perform cartilage-restoration procedures. The commercial opportunity is therefore driven by surgeon training and referral patterns as much as by the underlying patient population. [1]

Market constraints

The principal constraints are procedure complexity, reimbursement variability, the need for two surgical encounters, patient eligibility, and competition from less complex interventions.

MACI requires a biopsy procedure followed by implantation after manufacturing. Microfracture can be performed in a single procedure and has lower direct procedural complexity, although outcomes may be less durable in some patient groups. Osteochondral allografts can provide immediate structural tissue but depend on donor availability and have their own surgical and biological limitations.

What is the financial trajectory of MACI and Vericel?

MACI has been the primary growth engine for Vericel. The company also sells Epicel, an autologous cultured epidermal autograft used for severe burns. MACI has grown faster than Epicel and has become the larger contributor to revenue.

Vericel revenue trajectory

Fiscal year Total Vericel revenue Approximate MACI revenue MACI share of total revenue
2021 $126 million Approximately $86 million Approximately 68%
2022 $159 million Approximately $113 million Approximately 71%
2023 $193 million Approximately $141 million Approximately 73%

Figures are rounded from Vericel annual filings and company disclosures. [1]

Total revenue rose by approximately 27% in 2022 and 21% in 2023. MACI revenue growth was supported by procedure volume, expanded surgeon use, and broader commercial penetration.

Financial sensitivity

MACI's financial profile differs from that of a conventional pharmaceutical:

  • Revenue is recognized when product is delivered for implantation.
  • Demand is tied to scheduled procedures and manufacturing throughput.
  • Patient-specific production creates operational risk.
  • Failed manufacturing runs, rejected tissue samples, shipping problems, or canceled surgeries can affect revenue.
  • Gross margin depends on manufacturing utilization and production efficiency.
  • Commercial expansion requires sales personnel, surgeon education, tissue logistics, and payer support.

Vericel's MACI business therefore has operating leverage. Higher volumes can improve manufacturing absorption and sales productivity, but capacity expansion requires capital investment and quality-system execution.

The product's revenue concentration also creates company-level exposure. A manufacturing disruption, adverse reimbursement decision, product-quality event, or change in surgical practice could have a material effect on Vericel's results because MACI represents most of the company's revenue.

When does MACI lose exclusivity?

MACI does not have a conventional small-molecule patent cliff. It is regulated as a biologic and a cell-based tissue-engineered product. Market protection depends on a combination of regulatory exclusivity, manufacturing know-how, product-specific process controls, trademarks, patents, and practical barriers to developing a competing autologous cell product.

FDA regulatory exclusivity

The FDA approved MACI under a biologics license application. The standard reference-product data-exclusivity period for a new biologic is 12 years under the Biologics Price Competition and Innovation Act, subject to statutory rules and the product's regulatory classification. [3]

The practical date associated with 12-year reference-product exclusivity from the December 2016 approval is December 2028. That date should not be treated as a guaranteed market-opening date because:

  • MACI is a complex autologous cell product.
  • A follow-on product would need to satisfy the FDA's requirements for biosimilarity or interchangeability, if such a pathway is applicable.
  • The FDA may require a product-specific development program.
  • The absence of conventional biosimilar substitution rules for a surgical cell product may limit automatic replacement.
  • Patent and process protections could extend beyond regulatory exclusivity.

The exact regulatory pathway for a competing product would depend on the FDA's product classification, reference-product determination, and the similarity of the proposed manufacturing process.

Patent protection and manufacturing protection

Publicly available company filings do not establish a simple single patent-expiration date that defines MACI's commercial life. The relevant protection is likely distributed across:

  • Cell expansion and culture methods.
  • Seeding autologous chondrocytes onto a collagen membrane.
  • Scaffold composition and porcine collagen processing.
  • Preservation, transport, and implantation procedures.
  • Quality-control specifications.
  • Manufacturing know-how and validated production systems.

For MACI, trade secrets and operational capabilities may be more important than a single composition-of-matter patent. The product's patient-specific manufacturing process is difficult to replicate without validated procedures, tissue logistics, cleanroom capacity, release testing, and regulatory approval.

What is the Orange Book status of MACI?

MACI is not expected to have a conventional FDA Orange Book listing comparable to an orally administered small-molecule drug.

The Orange Book primarily identifies approved drug products and patent or exclusivity information relevant to abbreviated new drug applications. MACI is regulated under the biologics framework and is not a typical Orange Book-listed pharmaceutical product. Relevant regulatory exclusivity and biosimilar issues are generally evaluated through the FDA biologics framework rather than a standard Orange Book Paragraph IV process. [3,4]

Are there Paragraph IV challenges to MACI?

No conventional Paragraph IV challenge is publicly associated with MACI in the manner used for small-molecule drugs.

A Paragraph IV certification is an ANDA mechanism for challenging patents listed in the Orange Book. A competing autologous cell therapy would not ordinarily enter through a conventional ANDA. Potential competitors would instead confront the FDA's biologics requirements, clinical evidence expectations, manufacturing controls, and potentially patent litigation under standard patent-infringement statutes.

The absence of a Paragraph IV challenge does not mean MACI has no competitive risk. It means the relevant challenge mechanism is different.

How strong is the MACI patent estate?

MACI's commercial protection is best characterized as moderate to strong from a practical standpoint, but less transparent than the patent estate for a conventional pharmaceutical.

Strengths

  • Patient-specific manufacturing is difficult to copy at scale.
  • The product requires specialized tissue collection and transport.
  • The collagen scaffold and cellular manufacturing process are integrated.
  • Manufacturing quality and release testing create regulatory barriers.
  • Clinical adoption depends on surgeon training and procedural confidence.
  • A competitor must establish both product comparability and manufacturing reliability.

Weaknesses

  • The product does not have a classic small-molecule composition-of-matter patent barrier.
  • Autologous chondrocytes and collagen scaffolds are not unique biological concepts.
  • Competing cell therapies could use different scaffolds or manufacturing systems.
  • Osteochondral allografts and other surgical procedures do not need to copy MACI to compete.
  • Patent protection may be narrower than the full commercial product concept.

The most important risk is not necessarily literal copying of MACI. A competitor could pursue a different cell source, scaffold, delivery method, or cartilage-restoration workflow and avoid direct infringement while competing for the same surgical indication.

What formulations and delivery systems are protected by MACI?

MACI is a cellularized membrane rather than a conventional drug formulation. Its product architecture includes:

  • Autologous chondrocytes expanded outside the body.
  • A porcine collagen type I/III membrane.
  • Controlled cell seeding and culture.
  • Patient-specific product release.
  • Surgical placement over a prepared cartilage defect.

The commercial value lies in the combined product-and-process system. A competitor using a synthetic polymer scaffold, hydrogel, allogeneic cells, induced pluripotent stem-cell-derived chondrocytes, or a different implantation technique could potentially compete without duplicating the MACI membrane.

What patent litigation affects MACI?

There is no major publicly reported MACI patent litigation comparable to the high-value patent disputes surrounding blockbuster small-molecule drugs or monoclonal antibodies through the public information available for this analysis.

The litigation risk remains relevant in four areas:

  1. Process patents: disputes over chondrocyte expansion, seeding, or scaffold manufacturing.
  2. Scaffold patents: claims directed to collagen membranes or cellularized matrices.
  3. Trade-secret disputes: employee movement, manufacturing know-how, and process documentation.
  4. Regulatory litigation: disputes concerning FDA approval, exclusivity, or competitor entry.

The absence of prominent litigation reduces near-term legal overhang but does not remove the possibility of future disputes as the market develops.

Which companies are challenging MACI?

No company has established a U.S. commercial product that directly replicates MACI's FDA-approved autologous cultured chondrocyte-on-collagen-membrane model.

Competitive categories

Competitive category Representative examples Competitive effect
Microfracture Arthroscopic marrow-stimulation procedures Lower-cost, simpler alternative
Osteochondral allograft Tissue-bank graft products Structural graft option for larger defects
Autologous osteochondral transfer Mosaicplasty and OATS procedures Uses patient tissue without ex vivo expansion
ACI alternatives Autologous chondrocyte procedures using other delivery systems Potential procedural substitute
Cell and tissue engineering Academic and emerging commercial programs Longer-term technology risk
Knee arthroplasty Partial or total knee replacement Alternative for advanced disease

Vericel's principal current competition is procedural, not a direct biosimilar competitor. The company must defend the cartilage-restoration treatment pathway against lower-complexity procedures and against surgeons choosing not to use cell-based repair.

What generic entry risks exist for MACI?

The risk of a conventional generic launch is low. The more relevant risks are:

  • A competing autologous chondrocyte product.
  • A new scaffold-based cell therapy.
  • An allogeneic cartilage or cell product.
  • A more convenient single-surgery treatment.
  • Improved osteochondral allograft availability.
  • Payer pressure favoring less expensive procedures.
  • Clinical evidence showing limited incremental benefit in specific patient populations.

The highest-probability entry scenario is not a direct generic substitution after patent expiry. It is gradual market-share pressure from alternative cartilage-repair technologies and surgical options.

How does MACI compare with Epicel and other biologic products?

MACI and Epicel are both autologous cell therapies commercialized by Vericel, but their markets differ.

Factor MACI Epicel
Tissue source Cartilage biopsy Skin biopsy
Clinical use Knee cartilage repair Severe burns and extensive skin loss
Procedure Cartilage implantation Skin grafting
Market driver Elective orthopedic surgery Acute and medically necessary burn care
Growth profile Procedure-volume expansion Case volume and burn-center utilization
Revenue concentration Larger Vericel contributor Smaller contributor

MACI has greater elective-market expansion potential. Epicel benefits from a specialized market with high clinical need but a smaller patient population. The products diversify Vericel's technology base but do not eliminate concentration in autologous manufacturing.

What licensing deals and partnerships affect MACI?

The MACI platform originated from the ACI technology developed by Genzyme, later acquired by Sanofi. Vericel obtained rights to commercialize MACI in the United States through its acquisition of the related business and assets from Sanofi. The transaction gave Vericel access to the product, manufacturing capabilities, intellectual property, and commercial infrastructure needed to launch MACI. [1]

No large external licensing deal is required for the core MACI revenue model. Its economics depend primarily on direct product sales and manufacturing rather than royalty-bearing partnerships.

What is the FDA regulatory status of MACI?

MACI is FDA-approved for adults with symptomatic, full-thickness cartilage defects of the knee. It is not approved as a general treatment for osteoarthritis, diffuse cartilage degeneration, or all forms of knee pain.

The regulatory profile includes:

  • Biologics license application approval.
  • Autologous manufacturing.
  • Patient-specific product release.
  • Surgical implantation.
  • Use in a defined adult knee-cartilage population.
  • FDA oversight of manufacturing facilities and quality systems.

The regulatory burden provides meaningful protection against rapid competition. A rival must demonstrate not only clinical performance but also reproducible cell expansion, scaffold manufacturing, sterility, identity, potency, and release testing.

What are the generic launch scenarios for MACI?

Scenario 1: No direct competitor before 2028

This is the most favorable scenario for Vericel. MACI continues to grow through surgeon adoption, payer coverage, and manufacturing expansion. The principal risks are reimbursement and alternative procedures.

Scenario 2: Post-2028 follow-on biologic development

A competitor begins development after the regulatory exclusivity period. Entry remains several years away because clinical, manufacturing, and regulatory work would be substantial.

Scenario 3: Non-biosimilar cell therapy

A competitor develops a different cartilage-regeneration product. This may avoid direct MACI patent claims but compete for the same patients and surgeons.

Scenario 4: Procedural substitution

Microfracture, osteochondral grafts, or arthroplasty capture additional volume. This scenario could limit MACI growth without any competing drug launch.

What is the geographic coverage of MACI?

MACI's strongest commercial position is in the United States, where Vericel owns the established commercial infrastructure and FDA approval.

International expansion is more complex because:

  • Cell-therapy regulations differ by jurisdiction.
  • Manufacturing and shipping requirements are demanding.
  • Hospital reimbursement varies substantially.
  • Tissue procurement rules differ.
  • Local competitors may use different cartilage-repair technologies.
  • A centralized U.S. manufacturing model may not translate directly to Europe or Asia.

The U.S. market remains the principal source of MACI revenue and valuation exposure.

Key Takeaways

  • MACI is Vericel's leading commercial product and generated approximately $141 million of revenue in 2023.
  • Vericel's total revenue increased from approximately $126 million in 2021 to $193 million in 2023.
  • MACI has no conventional generic or Paragraph IV pathway.
  • The product's 12-year biologic reference-product exclusivity period points to December 2028 from its December 2016 approval, subject to statutory and regulatory interpretation.
  • Practical protection comes from patient-specific manufacturing, quality systems, tissue logistics, surgeon training, and regulatory complexity.
  • The largest competitive threats are alternative procedures and next-generation cartilage-regeneration products, not an immediate biosimilar.
  • MACI's financial trajectory depends on procedure growth, reimbursement, manufacturing capacity, and continued orthopedic adoption.
  • The product has meaningful commercial protection but does not present the same patent-cliff profile as a small-molecule drug with a composition-of-matter patent.

FAQs

Is MACI a drug or a medical device?

MACI is a biologic cell therapy regulated by the FDA under a biologics license application. It is not a conventional small-molecule drug or an ordinary medical device.

Does MACI require two surgeries?

The treatment generally involves a cartilage biopsy followed by a later implantation procedure after the patient's cells have been expanded and seeded onto the collagen membrane.

Can MACI treat knee osteoarthritis?

MACI is approved for specified symptomatic full-thickness cartilage defects in adults. It is not broadly approved for diffuse knee osteoarthritis.

Is MACI reimbursed by Medicare?

Coverage depends on the clinical circumstances, applicable Medicare policy, coding, payer requirements, and provider setting. Reimbursement is a key commercial variable for MACI adoption.

Could stem-cell cartilage products replace MACI?

Potentially. An allogeneic cell product, engineered cartilage implant, or single-surgery regenerative therapy could compete with MACI if it demonstrates adequate clinical outcomes, manufacturing reliability, FDA approval, and payer acceptance.

References

  1. Vericel Corporation. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.

  2. U.S. Food and Drug Administration. (2016). MACI: FDA prescribing information. U.S. Department of Health and Human Services.

  3. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. U.S. Department of Health and Human Services.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.